CNBX Pharmaceuticals Statistics
Total Valuation
CNBX has a market cap or net worth of $311,114. The enterprise value is $1.41 million.
| Market Cap | 311,114 |
| Enterprise Value | 1.41M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
CNBX has 31.11 million shares outstanding. The number of shares has increased by 235.76% in one year.
| Shares Outstanding | 31.11M |
| Shares Change (YoY) | +235.76% |
| Shares Change (QoQ) | +0.40% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 10.67% |
| Float | 27.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.35 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.03
| Current Ratio | 0.03 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0.66 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -1,509.70% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $270,120 |
| Profits Per Employee | -$604,084 |
| Employee Count | 2 |
| Asset Turnover | 4.55 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4.76M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.00% in the last 52 weeks. The beta is 0.79, so CNBX's price volatility has been lower than the market average.
| Beta (5Y) | 0.79 |
| 52-Week Price Change | -60.00% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 47.97 |
| Average Volume (20 Days) | 70,558 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CNBX had revenue of $540,239 and -$1.21 million in losses. Loss per share was -$0.05.
| Revenue | 540,239 |
| Gross Profit | 423,207 |
| Operating Income | -692,109 |
| Pretax Income | -1.15M |
| Net Income | -1.21M |
| EBITDA | -3.03M |
| EBIT | -3.14M |
| Loss Per Share | -$0.05 |
Balance Sheet
The company has $73,406 in cash and $1.29 million in debt, giving a net cash position of -$1.22 million or -$0.04 per share.
| Cash & Cash Equivalents | 73,406 |
| Total Debt | 1.29M |
| Net Cash | -1.22M |
| Net Cash Per Share | -$0.04 |
| Equity (Book Value) | -2.45M |
| Book Value Per Share | -0.08 |
| Working Capital | -2.45M |
Cash Flow
In the last 12 months, operating cash flow was -$175,502 and capital expenditures -$1,196, giving a free cash flow of -$176,698.
| Operating Cash Flow | -175,502 |
| Capital Expenditures | -1,196 |
| Free Cash Flow | -176,698 |
| FCF Per Share | -$0.01 |
Margins
Gross margin is 78.34%, with operating and profit margins of -128.11% and -223.64%.
| Gross Margin | 78.34% |
| Operating Margin | -128.11% |
| Pretax Margin | -213.09% |
| Profit Margin | -223.64% |
| EBITDA Margin | -561.12% |
| EBIT Margin | -581.63% |
| FCF Margin | -32.71% |
Dividends & Yields
CNBX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -235.76% |
| Shareholder Yield | -235.76% |
| Earnings Yield | -647.23% |
| FCF Yield | -94.66% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on May 12, 2022. It was a reverse split with a ratio of 1:120.
| Last Split Date | May 12, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:120 |
Scores
CNBX has an Altman Z-Score of -595.08 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -595.08 |
| Piotroski F-Score | 3 |